Systematic review and meta-analysis for the 2024 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis

• Published in: Modern rheumatology Vol. 34; no. 6; pp. 1079 - 1094
• Main Authors: Nakayama, Yoichi, Nagata, Wataru, Takeuchi, Yoichi, Fukui, Sho, Fujita, Yuya, Hosokawa, Yohei, Ueno, Masanobu, Ono, Kumiko, Sumitomo, Shuji, Tabuchi, Yuya, Nakanishi, Yuichiro, Saito, Shuntaro, Ikeuchi, Hiroko, Kawamori, Kazutaka, Sofue, Hideaki, Doi, Goro, Minami, Runa, Hirota, Tomoya, Minegishi, Kaoru, Maeshima, Keisuke, Motoyama, Ryo, Nakamura, Shohei, Suzuki, Shotaro, Nishioka, Norihiro, Wada, Takuma Tsuzuki, Onishi, Akira, Nishimura, Kenichi, Watanabe, Ryu, Yanai, Ryo, Kida, Takashi, Nishiwaki, Hiroki, Yajima, Nobuyuki, Kaneko, Yuko, Tanaka, Eiichi, Kawahito, Yutaka, Harigai, Masayoshi
• Format: Journal Article
• Language: English
• Published: England 15.10.2024
• Subjects: ozoralizumab; meta-analysis; clinical practice guidelines; systematic review; rheumatoid arthritis
• ISSN: 1439-7595; 1439-7609; 1439-7609
• DOI: 10.1093/mr/roae049

To update evidence on the efficacy and safety of disease-modifying antirheumatic drugs (DMARDs) and provide information to the taskforce for the 2024 update of the Japan College of Rheumatology (JCR) clinical practice guidelines (CPG) for the management of rheumatoid arthritis (RA). We searched various databases for randomised controlled trials on RA published until June 2022, with no language restriction. For each of the 15 clinical questions, 2 independent reviewers screened the articles, evaluated the core outcomes, and performed meta-analyses. Subcutaneous injection of methotrexate (MTX) showed similar efficacy to oral MTX in MTX-naïve RA patients. Ozoralizumab combined with MTX improved drug efficacy compared to the placebo in RA patients with inadequate response (IR) to csDMARD. Rituximab with and without concomitant csDMARDs showed similar efficacy to other bDMARDs in bDMARD-IR RA patients. Combined Janus kinase inhibitors and MTX achieved similar clinical responses and equal safety during a 4-year period compared to tumour necrosis factor inhibitors in MTX-IR RA patients. Biosimilars showed efficacy equivalent to that of the original bDMARDs in csDMARD-IR and bDMARD-IR RA patients. This systematic review provides latest evidence for the 2024 update of the JCR CPG for RA management.